Photo from wikipedia
To evaluate the 2‐year retention rate of golimumab compared with etanercept and adalimumab as second‐line biologic agent in rheumatoid arthritis (RA) patients who failed a previous tumor necrosis factor inhibitor… Click to show full abstract
To evaluate the 2‐year retention rate of golimumab compared with etanercept and adalimumab as second‐line biologic agent in rheumatoid arthritis (RA) patients who failed a previous tumor necrosis factor inhibitor (TNFi).
Keywords:
agent rheumatoid;
line biologic;
rheumatoid arthritis;
tumor necrosis;
biologic agent;
second line
Journal Title: International Journal of Rheumatic Diseases
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: International Journal of Rheumatic Diseases
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!